Showing results (51-60 of 205) with videos related to

Sort By:
Pageof 21
Bulletin Du Cancer|June 15, 2011
[KIT and KIT: from biology to clinical use]Elsa Curtit, Laura Mansi, Erika Viel, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|January 20, 2011
Mammography utilization in women aged 40-49 years: the French EDIFICE surveyXavier Pivot, François Eisinger, Jean-Yves Blay, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|January 20, 2011
Organized colorectal cancer screening programmes: how to optimize efficiency in the general populationAnne Calazel-Benque, Jérôme Viguier, Claire Roussel, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|January 20, 2011
Screening for prostate cancer: growth without controlFrançois Eisinger, Jean-Yves Blay, Xavier Pivot, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|January 20, 2011
Impact of general practitioners' sex and age on systematic recommendation for cancer screeningFrançois Eisinger, Xavier Pivot, Yvan Coscas, et al.
The British Journal of Nutrition|July 3, 2004
Malnutrition is an independent factor associated with nosocomial infectionsStéphane M Schneider, Patricia Veyres, Xavier Pivot, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|January 20, 2011
Breast cancer screening in women aged 50-74 years: is there room for improvement?Jean-François Morère, Xavier Pivot, Jérôme Viguier, et al.
Clinical Therapeutics|July 3, 2016
A Randomized Phase I Pharmacokinetic Study Comparing Biosimilar Candidate SB3 and Trastuzumab in Healthy Male SubjectsXavier Pivot, Elsa Curtit, Yoon Jung Lee, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2020
Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: Results from the french personalized reimbursement model database (2011-2018)Paul Cottu, Bruno Coudert, David Perol, et al.
Clinical Breast Cancer|November 30, 2021
The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBCChris Twelves, Rupert Bartsch, Noa Efrat Ben-Baruch, et al.
Pageof 21